This editorial refers to ‘Cardiovascular manifestations in men and women carrying a FBN1 mutation’, by D. Détaint et al., on page 2223

We are rapidly entering an era of personalized genomic medicine. The complete sequencing of the human genome was first announced >9 years ago, and soon afterwards the annotated human genome sequence was available online.1 Today, DNA analysis that was once considered onerous has become routine. Although not perfect, ‘next-generation’ techniques for rapid and low-cost sequencing have been applied to whole human genome determination. The use of massively parallel, high-throughput sequencing to analyse the human genome was first published in 2008 with a reduction in cost estimated from US$100 million to ∼US$1 million2. Soon afterwards, two additional whole human genome sequences were reported, with estimated costs reduced even further.3,4 Investigators recently reported whole human genome analysis by another next-generation technique, Sequencing by Oligonucleotide Ligation and Detection (SOLiD) to determine the cause of recessive Charcot–Marie–Tooth disease.5 The estimated cost for this herculean task was <US$50 000, more than the cost of focused analysis of the known genes in which mutations can cause Charcot–Marie–Tooth disease, but the emerging feasibility of this approach is remarkable. As the cost of large-scale genetic testing declines, it will inevitably be used more widely.

Despite profound success in the ability to perform next-generation DNA testing, its application to clinical medicine has been somewhat slower. Today, if a patient showed up in a physician's office with the full sequence of his or her ∼3 billion DNA nucleotide base pairs, its application to medical evaluation and treatment would be nearly impossible. The critical link between genetic analysis and clinical practice will come from large studies that analyse a range of phenotypes that associate with genotypes.

The study by Détaint and colleagues addresses this type of important resource.6 This international consortium of investigators with expertise in Marfan syndrome and related type-1 fibrillinopathies arose from the early efforts to produce a catalogue of FBN1 mutations.7 The Universal Mutation Database now has several locus-specific programmes, including one that focuses on FBN1 (www.umd.be/FBN1/). Both pathogenic mutations and non-pathogenic polymorphisms are designated, and clinical phenotypes are accrued along with the mutations. Similar online resources are available for many monogenic forms of cardiovascular diseases. This type of international collaboration results in far greater numbers than would be available at any single site. Such databases allow one to determine if a rare DNA variant has previously been reported and if it occurs in proximity to known mutations or polymorphisms.

FBN1 mutations typically result in Marfan syndrome, a systemic disorder of connective tissue characterized by its cardinal manifestations: aortic aneurysm, dislocation of the ocular lens, and long bone overgrowth.8,9 The cardiovascular features of this condition were first comprehensively described by one of the pioneers in Genetic Medicine, cardiologist Victor A. McKusick, 55 years ago.10 With only a stethoscope, chest X-rays, and autopsies to evaluate for cardiovascular disease, he reported a full spectrum of aortic and cardiac valve complications related to this condition among 105 people. Since then, affected and at-risk individuals have been evaluated for cardiovascular complications. Although yearly screening is generally recommended, the incidence of late-onset manifestations was previously not known.

Détaint and colleagues now provide data on the cardiovascular risk associated with FBN1 mutations among 965 individuals, excluding neonatal Marfan. While smaller studies have previously addressed the topic, this is by far the largest series for such analysis. Several important points deserve further emphasis. First, the apparent age of onset of ascending aortic dilatation continued throughout the entire span that was represented. Thus, lifelong echocardiographic screening for aortic enlargement should continue despite many years of normal aortic root dimension. The incidence of aortic dissection declined during the period of investigation since 1985, while the prevalence of aortic dilatation remained similar. At first glance, one might expect that this is due to increased use of prophylactic aortic root surgery. However, there was no significant change in the rates of surgical referral. Possible explanations for this include successful medical treatment, lifestyle modifications, or perhaps simply a decline in the inclusion of people with greater tendency to aortic dissection due to factors other than aortic root size.

Despite suspicion of increased prevalence of aortic aneurysm among affected men with Marfan syndrome compared with women, the evidence supporting this impression has previously been based on relatively small cohorts or anecdotal experience. The study by Détaint et al. addresses this topic in 965 people (53% men).6 Among this cohort, not only were men more likely than women to have ascending aortic dilatation at age ≤30 years (P = 0.0076), but aortic events (dissection and prophylactic surgery) were also more common among men compared with women, with an adjusted hazard ratio of 1.4. While men tended to have aortic dilatation at an earlier age than women, it is important to recognize that 96% of both men and women in this cohort had ascending aortic dilatation at age 60 years.

Mitral valve prolapse (MVP) is common in the general population and also occurs with type-1 fibrillinopathies. Early echocardiographic studies often greatly overestimated the prevalence of MVP because of incorrect assumptions that the valve was planar rather than saddle-shaped.11 Improved techniques for imaging, as well as greater recognition of the three-dimensional structure of the mitral valve and its annulus, have led to more accurate determinations of MVP.12 Population studies have found that women are more likely to have MVP than men.12 In this context, it is surprising that Détaint and colleagues did not find sex differences in MVP or other manifestations of mitral valve disease among this cohort of individuals. As with aortic disease, MVP was found to be an age-dependent phenotype with increasing prevalence among older subjects in their analysis.

Today there are several reasons to consider the use of clinical genetic testing for people with inherited cardiovascular diseases (Figure 1). For example, recognition of a responsible gene mutation may help to identify syndromic features, to confirm a clinical diagnosis, and to evaluate relatives who are at risk for the condition. However, caution with the use and interpretation of genetic tests is warranted, and genetic counselling should be included with its use. One challenge with regard to personalized genomic medicine is that most families with type-1 fibrillinopathies have a unique or private DNA mutation. This diverse group of disorders includes Marfan syndrome, familial ectopia lentis, familial mitral valve prolapse, MASS (mitral, aortic, skin, and skeletal features of Marfan syndrome), Shprintzen–Goldberg syndrome, some cases of Weill–Marchesani syndrome, and, most recently, the stiff skin syndrome. Attempts to correlate phenotypic manifestations among the fibrillinopathies to specific genotypes have generally failed, with a few notable exceptions. First, more severe manifestations are evident among people with an in-frame or missense FBN1 mutation in exons 24–32.13 Also, mutations that occur in close proximity to the encoded RGD motif in exon 37 of FBN1 result in congenital stiff skin syndrome, a disorder that appears to provide clues about the role of fibrillin-1 in scleroderma.14

Figure 1

Potential uses of a genetic test for inherited cardiovascular diseases.

Figure 1

Potential uses of a genetic test for inherited cardiovascular diseases.

The era of personalized genomic medicine will indeed reach full fruition when a genetic test result helps to determine the best therapy for an individual. Towards that goal, fibrillin-1 mutation or deficiency has been shown to increase transforming growth factor-β (TGF-β) activation and signalling, and therapies that diminish TGF-β effects improve several phenotypic features of fibrillin-1 mutation in murine models.15,16 Furthermore, selective blockade of the angiotensin II type-1 receptor similarly modulates TGF-β through overlap in post-receptor signalling.16,17 Similar observations in people have led to clinical trials investigating the efficacy of angiotensin II type-1 receptor antagonism in Marfan syndrome.18

Future directions for this research include determination of the additional genetic and environmental factors that influence outcomes, penetrance, age dependence, and variable expressivity of FBN1 mutations. Today, the finding of a FBN1 mutation cannot tell us when or even if a patient will develop cardiovascular manifestations such as mitral valve disease or ascending aortic dilatation. With lower costs and expanding use of genetic analysis, an era of personalized genomic medicine is moving closer but is not yet fully realized.

Conflict of interest: none declared.

References

1
Venter
JC
Adams
MD
Myers
EW
Li
PW
Mural
RJ
Sutton
GG
Smith
HO
Yandell
M
Evans
CA
Holt
RA
Gocayne
JD
Amanatides
P
Ballew
RM
Huson
DH
Wortman
JR
Zhang
Q
Kodira
CD
Zheng
XH
Chen
L
Skupski
M
Subramanian
G
Thomas
PD
Zhang
J
Gabor Miklos
GL
Nelson
C
Broder
S
Clark
AG
Nadeau
J
McKusick
VA
Zinder
N
Levine
AJ
Roberts
RJ
Simon
M
Slayman
C
Hunkapiller
M
Bolanos
R
Delcher
A
Dew
I
Fasulo
D
Flanigan
M
Florea
L
Halpern
A
Hannenhalli
S
Kravitz
S
Levy
S
Mobarry
C
Reinert
K
Remington
K
Abu-Threideh
J
Beasley
E
Biddick
K
Bonazzi
V
Brandon
R
Cargill
M
Chandramouliswaran
I
Charlab
R
Chaturvedi
K
Deng
Z
Di Francesco
V
Dunn
P
Eilbeck
K
Evangelista
C
Gabrielian
AE
Gan
W
Ge
W
Gong
F
Gu
Z
Guan
P
Heiman
TJ
Higgins
ME
Ji
RR
Ke
Z
Ketchum
KA
Lai
Z
Lei
Y
Li
Z
Li
J
Liang
Y
Lin
X
Lu
F
Merkulov
GV
Milshina
N
Moore
HM
Naik
AK
Narayan
VA
Neelam
B
Nusskern
D
Rusch
DB
Salzberg
S
Shao
W
Shue
B
Sun
J
Wang
Z
Wang
A
Wang
X
Wang
J
Wei
M
Wides
R
Xiao
C
Yan
C
Yao
A
Ye
J
Zhan
M
Zhang
W
Zhang
H
Zhao
Q
Zheng
L
Zhong
F
Zhong
W
Zhu
S
Zhao
S
Gilbert
D
Baumhueter
S
Spier
G
Carter
C
Cravchik
A
Woodage
T
Ali
F
An
H
Awe
A
Baldwin
D
Baden
H
Barnstead
M
Barrow
I
Beeson
K
Busam
D
Carver
A
Center
A
Cheng
ML
Curry
L
Danaher
S
Davenport
L
Desilets
R
Dietz
S
Dodson
K
Doup
L
Ferriera
S
Garg
N
Gluecksmann
A
Hart
B
Haynes
J
Haynes
C
Heiner
C
Hladun
S
Hostin
D
Houck
J
Howland
T
Ibegwam
C
Johnson
J
Kalush
F
Kline
L
Koduru
S
Love
A
Mann
F
May
D
McCawley
S
McIntosh
T
McMullen
I
Moy
M
Moy
L
Murphy
B
Nelson
K
Pfannkoch
C
Pratts
E
Puri
V
Qureshi
H
Reardon
M
Rodriguez
R
Rogers
YH
Romblad
D
Ruhfel
B
Scott
R
Sitter
C
Smallwood
M
Stewart
E
Strong
R
Suh
E
Thomas
R
Tint
NN
Tse
S
Vech
C
Wang
G
Wetter
J
Williams
S
Williams
M
Windsor
S
Winn-Deen
E
Wolfe
K
Zaveri
J
Zaveri
K
Abril
JF
Guigó
R
Campbell
MJ
Sjolander
KV
Karlak
B
Kejariwal
A
Mi
H
Lazareva
B
Hatton
T
Narechania
A
Diemer
K
Muruganujan
A
Guo
N
Sato
S
Bafna
V
Istrail
S
Lippert
R
Schwartz
R
Walenz
B
Yooseph
S
Allen
D
Basu
A
Baxendale
J
Blick
L
Caminha
M
Carnes-Stine
J
Caulk
P
Chiang
YH
Coyne
M
Dahlke
C
Mays
A
Dombroski
M
Donnelly
M
Ely
D
Esparham
S
Fosler
C
Gire
H
Glanowski
S
Glasser
K
Glodek
A
Gorokhov
M
Graham
K
Gropman
B
Harris
M
Heil
J
Henderson
S
Hoover
J
Jennings
D
Jordan
C
Jordan
J
Kasha
J
Kagan
L
Kraft
C
Levitsky
A
Lewis
M
Liu
X
Lopez
J
Ma
D
Majoros
W
McDaniel
J
Murphy
S
Newman
M
Nguyen
T
Nguyen
N
Nodell
M
Pan
S
Peck
J
Peterson
M
Rowe
W
Sanders
R
Scott
J
Simpson
M
Smith
T
Sprague
A
Stockwell
T
Turner
R
Venter
E
Wang
M
Wen
M
Wu
D
Wu
M
Xia
A
Zandieh
A
Zhu
X
The sequence of the human genome
Science
 , 
2001
, vol. 
291
 (pg. 
1304
-
1351
)
2
Wheeler
DA
Srinivasan
M
Egholm
M
Shen
Y
Chen
L
McGuire
A
He
W
Chen
YJ
Makhijani
V
Roth
GT
Gomes
X
Tartaro
K
Niazi
F
Turcotte
CL
Irzyk
GP
Lupski
JR
Chinault
C
Song
XZ
Liu
Y
Yuan
Y
Nazareth
L
Qin
X
Muzny
DM
Margulies
M
Weinstock
GM
Gibbs
RA
Rothberg
JM
The complete genome of an individual by massively parallel DNA sequencing
Nature
 , 
2008
, vol. 
452
 (pg. 
872
-
876
)
3
Wang
J
Wang
W
Li
R
Li
Y
Tian
G
Goodman
L
Fan
W
Zhang
J
Li
J
Guo
Y
Feng
B
Li
H
Lu
Y
Fang
X
Liang
H
Du
Z
Li
D
Zhao
Y
Hu
Y
Yang
Z
Zheng
H
Hellmann
I
Inouye
M
Pool
J
Yi
X
Zhao
J
Duan
J
Zhou
Y
Qin
J
Ma
L
Li
G
Zhang
G
Yang
B
Yu
C
Liang
F
Li
W
Li
S
Ni
P
Ruan
J
Li
Q
Zhu
H
Liu
D
Lu
Z
Li
N
Guo
G
Ye
J
Fang
L
Hao
Q
Chen
Q
Liang
Y
Su
Y
San
A
Ping
C
Yang
S
Chen
F
Li
L
Zhou
K
Ren
Y
Yang
L
Gao
Y
Yang
G
Li
Z
Feng
X
Kristiansen
K
Wong
GK
Nielsen
R
Durbin
R
Bolund
L
Zhang
X
Yang
H
The diploid genome sequence of an Asian individual
Nature
 , 
2008
, vol. 
456
 (pg. 
60
-
65
)
4
Bentley
DR
Balasubramanian
S
Swerdlow
HP
Smith
GP
Milton
J
Brown
CG
Hall
KP
Evers
DJ
Barnes
CL
Bignell
HR
Boutell
JM
Bryant
J
Carter
RJ
Keira Cheetham
R
Cox
AJ
Ellis
DJ
Flatbush
MR
Gormley
NA
Humphray
SJ
Irving
LJ
Karbelashvili
MS
Kirk
SM
Li
H
Liu
X
Maisinger
KS
Murray
LJ
Obradovic
B
Ost
T
Parkinson
ML
Pratt
MR
Rasolonjatovo
IM
Reed
MT
Rigatti
R
Rodighiero
C
Ross
MT
Sabot
A
Sankar
SV
Scally
A
Schroth
GP
Smith
ME
Smith
VP
Spiridou
A
Torrance
PE
Tzonev
SS
Vermaas
EH
Walter
K
Wu
X
Zhang
L
Alam
MD
Anastasi
C
Aniebo
IC
Bailey
DM
Bancarz
IR
Banerjee
S
Barbour
SG
Baybayan
PA
Benoit
VA
Benson
KF
Bevis
C
Black
PJ
Boodhun
A
Brennan
JS
Bridgham
JA
Brown
RC
Brown
AA
Buermann
DH
Bundu
AA
Burrows
JC
Carter
NP
Castillo
N
Chiara
ECM
Chang
S
Neil Cooley
R
Crake
NR
Dada
OO
Diakoumakos
KD
Dominguez-Fernandez
B
Earnshaw
DJ
Egbujor
UC
Elmore
DW
Etchin
SS
Ewan
MR
Fedurco
M
Fraser
LJ
Fuentes Fajardo
KV
Scott Furey
W
George
D
Gietzen
KJ
Goddard
CP
Golda
GS
Granieri
PA
Green
DE
Gustafson
DL
Hansen
NF
Harnish
K
Haudenschild
CD
Heyer
NI
Hims
MM
Ho
JT
Horgan
AM
Hoschler
K
Hurwitz
S
Ivanov
DV
Johnson
MQ
James
T
Huw Jones
TA
Kang
GD
Kerelska
TH
Kersey
AD
Khrebtukova
I
Kindwall
AP
Kingsbury
Z
Kokko-Gonzales
PI
Kumar
A
Laurent
MA
Lawley
CT
Lee
SE
Lee
X
Liao
AK
Loch
JA
Lok
M
Luo
S
Mammen
RM
Martin
JW
McCauley
PG
McNitt
P
Mehta
P
Moon
KW
Mullens
JW
Newington
T
Ning
Z
Ling Ng
B
Novo
SM
O'Neill
MJ
Osborne
MA
Osnowski
A
Ostadan
O
Paraschos
LL
Pickering
L
Pike
AC
Pike
AC
Chris Pinkard
D
Pliskin
DP
Podhasky
J
Quijano
VJ
Raczy
C
Rae
VH
Rawlings
SR
Chiva Rodriguez
A
Roe
PM
Rogers
J
Rogert Bacigalupo
MC
Romanov
N
Romieu
A
Roth
RK
Rourke
NJ
Ruediger
ST
Rusman
E
Sanches-Kuiper
RM
Schenker
MR
Seoane
JM
Shaw
RJ
Shiver
MK
Short
SW
Sizto
NL
Sluis
JP
Smith
MA
Ernest Sohna Sohna
J
Spence
EJ
Stevens
K
Sutton
N
Szajkowski
L
Tregidgo
CL
Turcatti
G
Vandevondele
S
Verhovsky
Y
Virk
SM
Wakelin
S
Walcott
GC
Wang
J
Worsley
GJ
Yan
J
Yau
L
Zuerlein
M
Rogers
J
Mullikin
JC
Hurles
ME
McCooke
NJ
West
JS
Oaks
FL
Lundberg
PL
Klenerman
D
Durbin
R
Smith
AJ
Accurate whole human genome sequencing using reversible terminator chemistry
Nature
 , 
2008
, vol. 
456
 (pg. 
53
-
59
)
5
Lupski
JR
Reid
JG
Gonzaga-Jauregui
C
Rio Deiros
D
Chen
DCY
Nazareth
L
Bainbridge
M
Dinh
H
Jing
C
Wheeler
DA
McGuire
AL
Zhang
F
Stankiewicz
P
Halperin
JJ
Yang
C
Gehman
C
Guo
D
Irikat
RK
Tom
W
Fantin
NJ
Muzny
DM
Gibbs
RA
Whole-genome sequencing in a patient with Charcot–Marie–Tooth Neuropathy
N Engl J Med
 , 
2010
, vol. 
362
 (pg. 
1181
-
1191
)
6
Détaint
D
Faivre
L
Collod-Beroud
G
Child
AH
Loeys
BL
Binquet
C
Gautier
E
Arbustini
E
Mayer
K
Arslan-Kirchner
M
Stheneur
C
Halliday
D
Beroud
C
Bonithon-Kopp
C
Claustres
M
Plauchu
H
Robinson
PN
Kiotsekoglou
A
De Backer
J
Adès
L
Francke
U
De Paepe
A
Boileau
C
Jondeau
G
Cardiovascular manifestations in men and women carrying a FBN1 mutation
Eur Heart J
 , 
2010
, vol. 
31
 (pg. 
2223
-
2229
)
7
Collod
G
Beroud
C
Soussi
T
Junien
C
Boileau
C
Software and database for the analysis of mutations in the human FBN1 gene
Nucleic Acids Res
 , 
1996
, vol. 
24
 (pg. 
137
-
140
)
8
Judge
DP
Dietz
HC
Marfan's syndrome
Lancet
 , 
2005
, vol. 
366
 (pg. 
1965
-
1976
)
9
Dietz
HC
Pyeritz
RE
Hall
BD
Cadle
RG
Hamosh
A
Schwartz
J
Meyers
DA
Francomano
CA
The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15–q21.3
Genomics
 , 
1991
, vol. 
9
 (pg. 
355
-
361
)
10
McKusick
VA
The cardiovascular aspects of Marfan's syndrome
Circulation
 , 
1955
, vol. 
11
 pg. 
321
 
11
Levine
R
Triulzi
M
Harrigan
P
Weyman
A
The relationship of mitral annular shape to the diagnosis of mitral valve prolapse
Circulation
 , 
1987
, vol. 
75
 (pg. 
756
-
767
)
12
Freed
LA
Levy
D
Levine
RA
Larson
MG
Evans
JC
Fuller
DL
Lehman
B
Benjamin
EJ
Prevalence and clinical outcome of mitral-valve prolapse
N Engl J Med
 , 
1999
, vol. 
341
 (pg. 
1
-
7
)
13
Faivre
L
Collod-Beroud
G
Loeys
BL
Child
A
Binquet
C
Gautier
E
Callewaert
B
Arbustini
E
Mayer
K
Arslan-Kirchner
M
Kiotsekoglou
A
Comeglio
P
Marziliano
N
Dietz
HC
Halliday
D
Beroud
C
Bonithon-Kopp
C
Claustres
M
Muti
C
Plauchu
H
Robinson
PN
Ades
LC
Biggin
A
Benetts
B
Brett
M
Holman
KJ
De Backer
J
Coucke
P
Francke
U
De Paepe
A
Jondeau
G
Boileau
C
Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study
Am J Hum Genet
 , 
2007
, vol. 
81
 (pg. 
454
-
466
)
14
Loeys
BL
Gerber
EE
Riegert-Johnson
D
Iqbal
S
Whiteman
P
McConnell
V
Chillakuri
CR
Macaya
D
Coucke
PJ
De Paepe
A
Judge
DP
Wigley
F
Davis
EC
Mardon
HJ
Handford
P
Keene
DR
Sakai
LY
Dietz
HC
Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome
Sci Transl Med
 , 
2010
, vol. 
2
 pg. 
23ra20
 
15
Ng
CM
Cheng
A
Myers
LA
Martinez-Murillo
F
Jie
C
Bedja
D
Gabrielson
KL
Hausladen
JM
Mecham
RP
Judge
DP
Dietz
HC
TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome
J Clin Invest
 , 
2004
, vol. 
114
 (pg. 
1586
-
1592
)
16
Habashi
JP
Judge
DP
Holm
TM
Cohn
RD
Loeys
BL
Cooper
TK
Myers
L
Klein
EC
Liu
G
Calvi
C
Podowski
M
Neptune
ER
Halushka
MK
Bedja
D
Gabrielson
K
Rifkin
DB
Carta
L
Ramirez
F
Huso
DL
Dietz
HC
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Science
 , 
2006
, vol. 
312
 (pg. 
117
-
121
)
17
Cohn
RD
van Erp
C
Habashi
JP
Soleimani
AA
Klein
EC
Lisi
MT
Gamradt
M
ap Rhys
CM
Holm
TM
Loeys
BL
Ramirez
F
Judge
DP
Ward
CW
Dietz
HC
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states
Nat Med
 , 
2007
, vol. 
13
 (pg. 
204
-
210
)
18
Brooke
BS
Habashi
JP
Judge
DP
Patel
N
Loeys
B
Dietz
HC
3rd
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome
N Engl J Med
 , 
2008
, vol. 
358
 (pg. 
2787
-
2795
)

Author notes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
doi:10.1093/eurheartj/ehq258

Supplementary data

Comments

0 Comments